CA2967094C - Method for removing cytokines from blood with surface immobilized polysaccharides - Google Patents
Method for removing cytokines from blood with surface immobilized polysaccharides Download PDFInfo
- Publication number
- CA2967094C CA2967094C CA2967094A CA2967094A CA2967094C CA 2967094 C CA2967094 C CA 2967094C CA 2967094 A CA2967094 A CA 2967094A CA 2967094 A CA2967094 A CA 2967094A CA 2967094 C CA2967094 C CA 2967094C
- Authority
- CA
- Canada
- Prior art keywords
- blood
- beads
- heparin
- substrate
- cytokine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 139
- 239000008280 blood Substances 0.000 title claims abstract description 139
- 238000000034 method Methods 0.000 title claims abstract description 72
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 62
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 62
- 150000004676 glycans Chemical class 0.000 title claims description 39
- 229920001282 polysaccharide Polymers 0.000 title claims description 39
- 239000005017 polysaccharide Substances 0.000 title claims description 39
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 104
- 229960002897 heparin Drugs 0.000 claims abstract description 104
- 229920000669 heparin Polymers 0.000 claims abstract description 103
- 239000000758 substrate Substances 0.000 claims abstract description 65
- 244000052769 pathogen Species 0.000 claims abstract description 47
- 239000003463 adsorbent Substances 0.000 claims abstract description 46
- 239000007787 solid Substances 0.000 claims abstract description 29
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 21
- 229920002971 Heparan sulfate Polymers 0.000 claims abstract description 15
- 210000002966 serum Anatomy 0.000 claims abstract description 11
- 239000011324 bead Substances 0.000 claims description 135
- 238000001179 sorption measurement Methods 0.000 claims description 54
- -1 polyethylene Polymers 0.000 claims description 22
- 239000004698 Polyethylene Substances 0.000 claims description 20
- 229920000573 polyethylene Polymers 0.000 claims description 20
- 239000000835 fiber Substances 0.000 claims description 18
- 150000001720 carbohydrates Chemical class 0.000 claims description 16
- 235000014633 carbohydrates Nutrition 0.000 claims description 15
- 238000009792 diffusion process Methods 0.000 claims description 13
- 229920001661 Chitosan Polymers 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 8
- 239000004744 fabric Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 7
- 229920001247 Reticulated foam Polymers 0.000 claims description 6
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 108010055166 Chemokine CCL5 Proteins 0.000 claims description 4
- 102000001327 Chemokine CCL5 Human genes 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 108090001007 Interleukin-8 Proteins 0.000 claims description 3
- 239000002156 adsorbate Substances 0.000 abstract description 14
- 125000003636 chemical group Chemical group 0.000 abstract description 3
- 230000000274 adsorptive effect Effects 0.000 abstract description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 24
- 239000011148 porous material Substances 0.000 description 21
- 102100040247 Tumor necrosis factor Human genes 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 15
- 239000012528 membrane Substances 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 239000004019 antithrombin Substances 0.000 description 8
- 239000012131 assay buffer Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000002885 thrombogenetic effect Effects 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- 230000035602 clotting Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 238000003380 quartz crystal microbalance Methods 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 235000011089 carbon dioxide Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 4
- 210000000601 blood cell Anatomy 0.000 description 4
- 230000023555 blood coagulation Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000010408 film Substances 0.000 description 4
- 239000012510 hollow fiber Substances 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000002965 anti-thrombogenic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000005056 compaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012286 potassium permanganate Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 3
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 102000045341 human CCL5 Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000001453 nonthrombogenic effect Effects 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920010741 Ultra High Molecular Weight Polyethylene (UHMWPE) Polymers 0.000 description 1
- 239000004699 Ultra-high molecular weight polyethylene Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000013132 cardiothoracic surgery Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000033383 cell-cell recognition Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007485 conventional hemodialysis Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 1
- MLUCVPSAIODCQM-UHFFFAOYSA-N crotonaldehyde Natural products CC=CC=O MLUCVPSAIODCQM-UHFFFAOYSA-N 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 230000001951 hemoperfusion Effects 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000052620 human IL10 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 238000008995 multiplex Luminex assay kit Methods 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005424 photoluminescence Methods 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/362—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits changing physical properties of target cells by binding them to added particles to facilitate their subsequent separation from other cells, e.g. immunoaffinity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3672—Means preventing coagulation
- A61M1/3673—Anticoagulant coating, e.g. Heparin coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3687—Chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/0057—Special media to be introduced, removed or treated retained by adsorption
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26567509P | 2009-12-01 | 2009-12-01 | |
| US61/265,675 | 2009-12-01 | ||
| CA2782311A CA2782311C (en) | 2009-12-01 | 2010-12-01 | Method for removing cytokines from blood with surface immobilized polysaccharides |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2782311A Division CA2782311C (en) | 2009-12-01 | 2010-12-01 | Method for removing cytokines from blood with surface immobilized polysaccharides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2967094A1 CA2967094A1 (en) | 2011-06-09 |
| CA2967094C true CA2967094C (en) | 2022-08-16 |
Family
ID=43731827
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2782311A Active CA2782311C (en) | 2009-12-01 | 2010-12-01 | Method for removing cytokines from blood with surface immobilized polysaccharides |
| CA2967094A Active CA2967094C (en) | 2009-12-01 | 2010-12-01 | Method for removing cytokines from blood with surface immobilized polysaccharides |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2782311A Active CA2782311C (en) | 2009-12-01 | 2010-12-01 | Method for removing cytokines from blood with surface immobilized polysaccharides |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US8758286B2 (enExample) |
| EP (1) | EP2509604B1 (enExample) |
| JP (2) | JP5925693B2 (enExample) |
| KR (2) | KR101716241B1 (enExample) |
| CN (2) | CN106178161B (enExample) |
| AU (1) | AU2010326028B2 (enExample) |
| CA (2) | CA2782311C (enExample) |
| ES (1) | ES2861359T3 (enExample) |
| WO (1) | WO2011068897A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006325531B2 (en) | 2005-12-13 | 2012-04-19 | Exthera Medical Corporation | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
| WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
| US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
| US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US12089589B2 (en) | 2009-10-12 | 2024-09-17 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| CA2782311C (en) | 2009-12-01 | 2017-06-27 | Robert S. Ward | Method for removing cytokines from blood with surface immobilized polysaccharides |
| WO2011133099A1 (en) * | 2010-04-21 | 2011-10-27 | Exthera Medical Llc | Method for removal of mrsa from blood |
| ES2959120T3 (es) | 2010-08-25 | 2024-02-20 | Hemanext Inc | Método para potenciar la calidad y la supervivencia de glóbulos rojos durante el almacenamiento |
| EP3539381B1 (en) | 2010-11-05 | 2023-05-24 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
| EP2682140A4 (en) * | 2011-03-04 | 2014-07-30 | Dainippon Ink & Chemicals | SUGAR-RECOVILIZED POLYMER SUBSTRATE FOR VIRUS REMOVAL AND METHOD FOR REMOVING VIRUSES |
| US9067004B2 (en) | 2011-03-28 | 2015-06-30 | New Health Sciences, Inc. | Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly |
| GB2484764B (en) | 2011-04-14 | 2012-09-05 | Verinata Health Inc | Normalizing chromosomes for the determination and verification of common and rare chromosomal aneuploidies |
| WO2013023156A1 (en) | 2011-08-10 | 2013-02-14 | New Health Sciences, Inc. | Integrated leukocyte, oxygen and/or co2 depletion, and plasma separation filter device |
| EP2776013B8 (en) | 2011-11-08 | 2023-08-30 | The Board of Trustees of the University of Arkansas | Methods and compositions for x-ray induced release from ph sensitive liposomes |
| US9549953B2 (en) * | 2011-12-08 | 2017-01-24 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
| EP2861273B1 (en) | 2012-06-13 | 2017-08-23 | ExThera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
| KR101427700B1 (ko) * | 2012-06-29 | 2014-08-07 | 주식회사 아모그린텍 | 사이토카인 흡착시트, 그 제조방법 및 이를 이용한 혈액 필터 |
| WO2014091002A1 (en) * | 2012-12-14 | 2014-06-19 | Gambro Lundia Ab | Cleaning of biological fluid |
| CA2902061C (en) | 2013-02-28 | 2023-08-08 | New Health Sciences, Inc. | Gas depletion and gas addition devices for blood treatment |
| EP3013445B1 (en) * | 2013-06-24 | 2019-11-06 | ExThera Medical Corporation | Blood filtration system containing mannose coated substrate |
| CN103285826A (zh) * | 2013-06-28 | 2013-09-11 | 天津优纳斯生物科技有限公司 | 一种用于抑制肿瘤生长与转移的血液净化吸附剂及其应用 |
| MX382486B (es) * | 2013-11-08 | 2025-03-13 | Exthera Medical Corp | Métodos para diagnosticar enfermedades infecciosas usando medio de adsorción. |
| WO2015113699A1 (en) * | 2014-01-30 | 2015-08-06 | Fresenius Hemocare Italia Srl | Filtering device |
| JP6728536B2 (ja) * | 2014-03-31 | 2020-07-22 | ゾール メディカル コーポレイションＺＯＬＬ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ | 蘇生後症候群を治療するための炎症性バイオマーカーの血液濾過 |
| JP2017513636A (ja) * | 2014-04-24 | 2017-06-01 | エクスセラ メディカル コーポレイション | 高流量を用いて血液から細菌を除去するための方法 |
| US10857283B2 (en) | 2014-09-22 | 2020-12-08 | Exthera Medical Corporation | Wearable hemoperfusion device |
| WO2016145210A1 (en) | 2015-03-10 | 2016-09-15 | New Health Sciences, Inc. | Oxygen reduction disposable kits, devices and methods of use thereof |
| US12109346B2 (en) * | 2015-03-27 | 2024-10-08 | Eliaz Therapeutics, Inc. | Galectin-3 plasmapheresis therapy |
| IL285359B2 (en) | 2015-04-23 | 2024-01-01 | Hemanext Inc | Anaerobic blood storage containers |
| PT3297641T (pt) * | 2015-05-18 | 2025-10-09 | Hemanext Inc | Métodos de armazenamento de sangue total e respetivas composições |
| US20180318337A1 (en) * | 2015-11-04 | 2018-11-08 | Duke University | Polycationic polymers for use in treating and detecting cancer |
| US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
| US10786615B2 (en) | 2016-03-02 | 2020-09-29 | Exthera Medical Corporation | Method for treating drug intoxication |
| JP6759679B2 (ja) * | 2016-04-25 | 2020-09-23 | 日立化成株式会社 | 分離材及びカラム |
| CN109195632A (zh) | 2016-05-27 | 2019-01-11 | 新健康科学股份有限公司 | 厌氧血液储存和病原体失活方法 |
| IL263695B2 (en) * | 2016-06-23 | 2023-03-01 | Hemanext Inc | Methods for treating side effects in patient populations that need transfusions |
| CN106771231B (zh) * | 2016-11-23 | 2019-02-12 | 江南大学 | 糖芯片在检测沙门氏菌或筛选沙门氏菌拮抗剂中的应用 |
| US12447464B2 (en) | 2016-12-22 | 2025-10-21 | Duke University | Polycationic microfibers and methods of using the same |
| CN107397961B (zh) * | 2017-09-05 | 2020-10-16 | 陕西师范大学 | 一种提高聚乙烯亚胺抗大肠杆菌性能的方法 |
| EP3473327A1 (en) * | 2017-10-19 | 2019-04-24 | 3M Innovative Properties Company | Integrated fluid treatment device, and process using such device |
| CN112088023B (zh) | 2018-01-05 | 2024-05-14 | 帕斯艾克斯公司 | 用于捕获和去除流体中的疾病物质的装置 |
| DE102019106651A1 (de) * | 2019-03-15 | 2020-09-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Behandlungsvorrichtung und -verfahren zur extrakorporalen, Immuntoleranz-steigernden Blutbehandlung |
| JP2022534191A (ja) * | 2019-05-16 | 2022-07-28 | エクスセラ メディカル コーポレイション | 内皮糖衣構造を調節するための方法 |
| EP4072613A4 (en) | 2019-12-12 | 2024-06-05 | Stavro Medical, Inc. | SYRINGE-BASED SYSTEMS FOR MANUAL EXTRACORPOREAL BLOOD TREATMENT AND BATCH PROCESSING METHODS |
| FR3109734B1 (fr) * | 2020-05-04 | 2025-04-11 | Univ Claude Bernard Lyon | Système de dialyse pour le traitement du sepsis |
| CA3194403A1 (en) | 2020-10-01 | 2022-04-07 | Steven Josephs | Reduced leaching of a ligand |
| US11224858B1 (en) | 2020-10-01 | 2022-01-18 | Immunicom, Inc. | Reduced leaching of a ligand |
| US20220125381A1 (en) * | 2020-10-23 | 2022-04-28 | Boston Scientific Scimed, Inc. | Medical devices and methods for monitoring and treatment with synthetic polymers exhibiting specific binding |
| WO2022216510A1 (en) * | 2021-04-06 | 2022-10-13 | Exthera Medical Corporation | Filtration media |
| CN114011389B (zh) * | 2021-12-08 | 2023-10-31 | 广州康盛生物科技股份有限公司 | 一种用于脓毒血症的血液净化材料及其制备方法和应用 |
| WO2025122575A1 (en) | 2023-12-05 | 2025-06-12 | Exthera Medical Corporation | Treatment for disease modification |
Family Cites Families (153)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB217812A (en) | 1923-09-25 | 1924-06-26 | John Henry Delaney | Improvements relating to the production of vermiculated appearance in artificial stone and like building materials |
| US3782382A (en) | 1972-02-03 | 1974-01-01 | K N Enterprises Inc | Means for blood administration and the like |
| US4103685A (en) | 1976-01-05 | 1978-08-01 | Lupien Paul J | Method and apparatus for extravascular treatment of blood |
| JPS54127493U (enExample) | 1978-02-25 | 1979-09-05 | ||
| JPS6040926B2 (ja) | 1979-07-24 | 1985-09-13 | 三菱重工業株式会社 | マンドレルバ−の自動サポ−ト装置 |
| US4430496A (en) | 1980-01-17 | 1984-02-07 | Varian Associates, Inc. | Strong anion exchange composition and methods |
| US4415665A (en) | 1980-12-12 | 1983-11-15 | Pharmacia Fine Chemicals Ab | Method of covalently binding biologically active organic substances to polymeric substances |
| JPS5853757A (ja) | 1981-09-25 | 1983-03-30 | Denki Kagaku Kogyo Kk | 免疫アフイニテイクロマトグラフイ−用吸着体及びその製法 |
| SE8200751L (sv) | 1982-02-09 | 1983-08-10 | Olle Larm | Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter |
| JPS58146354A (ja) | 1982-02-26 | 1983-08-31 | 日機装株式会社 | 体液浄化器の製造法 |
| US4820302A (en) | 1982-04-22 | 1989-04-11 | Sterling Drug Inc. | Bio compatible and blood compatible materials and methods |
| CA1221307A (en) * | 1982-12-02 | 1987-05-05 | Nobutaka Tani | Adsorbent and process for preparing the same |
| JPS59227827A (ja) * | 1983-06-10 | 1984-12-21 | Nippon Koutai Kenkyusho:Kk | マラリア原虫由来糖鎖関連抗原及びその製造法 |
| DE3609021A1 (de) | 1985-03-25 | 1986-09-25 | Bio-Rad Laboratories, Inc., Richmond, Calif. | Chromatographisches trennmedium fuer die schnelle analyse von kleinen proben |
| DE3519011A1 (de) | 1985-05-25 | 1986-11-27 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung eines materials zur affinitaetschromatographie |
| CA1327963C (en) | 1987-09-08 | 1994-03-22 | Ryuichi Yokohari | Autoantibody adsorbent and apparatus for removing autoantibodies using the same |
| DE3853219T2 (de) * | 1987-11-20 | 1995-06-29 | Kanegafuchi Chemical Ind | Methode zur Entfernung von Serum-Amyloid-Protein. |
| US4955870A (en) | 1988-08-23 | 1990-09-11 | Ridderheim Kristen A | Hypodermic syringe with retractable needle |
| WO1991004086A1 (en) | 1989-09-18 | 1991-04-04 | Cuno, Incorporated | Filter media and use for pyrogen removal |
| JPH0489500A (ja) | 1990-07-31 | 1992-03-23 | Kirin Brewery Co Ltd | アフィニティクロマトグラフィーによる物質の精製法および精製装置 |
| SE469256B (sv) | 1991-02-18 | 1993-06-14 | Medscand Ab | Rengoeringsprodukt |
| EP0533946A4 (en) | 1991-03-26 | 1995-06-07 | Otsuka Pharma Co Ltd | Adsorbed cellular fibronectin and process for separating and purifying fibronectins |
| US5211850A (en) * | 1991-07-26 | 1993-05-18 | Research Medical, Inc. | Plasma filter sorbent system for removal of components from blood |
| DE4217917A1 (de) | 1992-05-30 | 1993-12-02 | Job Prof Dr Med Harenberg | Immobilisation von chemisch kovalent gebundenem Heparin an Polymere mit Arylresten im Polymer |
| JPH0640926A (ja) | 1992-07-24 | 1994-02-15 | Chemo Sero Therapeut Res Inst | Ｃ型肝炎ウイルスの除去方法 |
| DE4331358A1 (de) * | 1992-10-12 | 1994-04-14 | Braun Melsungen Ag | Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten |
| US5344455A (en) | 1992-10-30 | 1994-09-06 | Medtronic, Inc. | Graft polymer articles having bioactive surfaces |
| US5437861A (en) | 1993-03-16 | 1995-08-01 | Applied Immune Sciences, Inc. | Removal of selected factors from whole blood or its components; and prevention and treatment of septic shock syndrome |
| JP2643823B2 (ja) | 1993-03-25 | 1997-08-20 | 有限会社 エンゼル総合研究所 | 吸着材料及びその製造方法 |
| NO931809L (no) | 1993-05-19 | 1994-11-21 | Norsk Hydro As | Hemofilter |
| US5447859A (en) | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
| US5753227A (en) | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
| CN1130386A (zh) | 1993-08-19 | 1996-09-04 | 美国3M公司 | 肝素官能亲合性载体 |
| JPH07178161A (ja) | 1993-12-24 | 1995-07-18 | Terumo Corp | 医療器具 |
| EP0810027B1 (en) | 1995-02-16 | 2002-06-05 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Adsorbent for tumor necrosis factor alpha, method of removal by adsorption, and adsorption device using said adsorbent |
| SE9501056D0 (sv) | 1995-03-23 | 1995-03-23 | Probi Ab | Epithelial adherent lactobacilli |
| US6312907B1 (en) | 1995-04-24 | 2001-11-06 | The Texas A & M University System | DbpA compositions and methods of use |
| WO1996040857A1 (en) | 1995-06-07 | 1996-12-19 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
| US6544727B1 (en) | 1995-06-07 | 2003-04-08 | Cerus Corporation | Methods and devices for the removal of psoralens from blood products |
| WO1997000969A1 (de) | 1995-06-20 | 1997-01-09 | Johannes Schumacher | Verfahren und vorrichtung zur bestimmung der aktivität von enzymen in flüssigkeiten, beziehungsweise der konzentration und/oder aktivität von inhibitoren in flüssigkeiten |
| EP0796865B1 (en) * | 1996-03-18 | 2003-06-04 | Kaneka Corporation | Adsorbent and method for removing chemokines of the CC subtype from body fluids |
| RU2089283C1 (ru) | 1996-03-23 | 1997-09-10 | Научно-исследовательская фирма "Ультрасан" | Био-, гемосовместимые сорбенты на основе сверхсшитых полимеров стирола с модифицированной поверхностью, способ их получения (варианты) и способ получения матрицы сорбента |
| SE507028C2 (sv) | 1996-08-06 | 1998-03-16 | Medicarb Ab | Ny medicinsk användning |
| AU5811498A (en) | 1996-12-31 | 1998-07-31 | Robert L. Stephon | Microsphere-enhanced immunoassay for the detection of veterinary diseases |
| US20010018179A1 (en) | 1998-01-06 | 2001-08-30 | Derek J. Hei | Batch devices for the reduction of compounds from biological compositions containing cells and methods of use |
| US20010009756A1 (en) | 1998-01-06 | 2001-07-26 | Derek Hei | Flow devices for the reduction of compounds from biological compositions and methods of use |
| KR20010005686A (ko) * | 1997-03-25 | 2001-01-15 | 후루타 타케시 | Ｃ형 간염 바이러스 제거용 흡착재, 흡착장치 및 흡착방법 |
| DK0984785T3 (da) * | 1997-05-27 | 2006-01-30 | Sanofi Aventis | Anvendelse af oligosaccharid til forhindring af blodkoagulation i ekstrakorporale blodkredslöb |
| US6465170B2 (en) | 1997-06-13 | 2002-10-15 | Baxter Aktiengesellschaft | Method for depleting viral and molecular pathogens in a biological material |
| EP0887061A1 (en) | 1997-06-28 | 1998-12-30 | The Procter & Gamble Company | Faecal collector |
| US6197568B1 (en) | 1997-07-29 | 2001-03-06 | The Regents Of The University Of Michigan | Method and compositions for isolation, diagnosis and treatment of polyanion-binding microorganisms |
| US20020197249A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood products |
| US20020159995A1 (en) * | 1997-07-30 | 2002-10-31 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing |
| US20020197250A1 (en) * | 2001-04-10 | 2002-12-26 | Renal Tech International | Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
| US6053894A (en) | 1997-08-04 | 2000-04-25 | Shadd, Jr.; Daniel L. | Hypodermic syringe |
| US7611831B2 (en) * | 1998-01-06 | 2009-11-03 | Cerus Corporation | Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix |
| US6136424A (en) * | 1998-02-06 | 2000-10-24 | Renal Tech International, Llc | Method of and material for purification of physiological liquids of organism, and method of producing the material |
| GB9804632D0 (en) | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| US8197430B1 (en) * | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
| JP2000086688A (ja) | 1998-09-04 | 2000-03-28 | Ngk Insulators Ltd | パルボウイルス吸着糖鎖リガンドおよびこれを利用したパルボウイルス除去装置 |
| NO984143L (no) | 1998-09-09 | 2000-03-10 | Norsk Hydro As | Ny prosess for å fremstille overflatemodifiserende stoffer |
| WO2000023792A1 (en) | 1998-10-19 | 2000-04-27 | Cbd Technologies Ltd. | Methods of concentrating microorganisms using affinity separation |
| EP1057529A4 (en) | 1998-12-22 | 2004-08-25 | Toray Industries | MATERIALS FOR THE DISPOSAL OF BACTERIAL COMPONENTS |
| US6659289B1 (en) * | 1998-12-24 | 2003-12-09 | Toray Industries, Inc. | Hemocathartic column for purifying blood |
| JP2000217575A (ja) | 1999-02-01 | 2000-08-08 | Masashi Funayama | 生理活性物質、ヒト血球分化細胞およびヒト細胞の吸着体。 |
| DE19916352A1 (de) | 1999-04-12 | 2000-10-19 | Braun Melsungen Ag | Entfernung von hüllehaltigen Viren aus Blut, Plasma oder Serum |
| WO2000066260A1 (en) | 1999-04-28 | 2000-11-09 | Toray Industries, Inc. | Materials for eliminating cannabinoids and columns for the elimination of cannabinoids with the use of the same |
| EP1219639A4 (en) | 1999-09-08 | 2009-03-25 | Toray Industries | CIPO - Patent |
| SE515295C2 (sv) | 1999-11-23 | 2001-07-09 | Medicarb Ab | Förfarande för framställning av konjugat av en biologiskt aktiv polysackarid och ett fast substrat, samt sådana konjugat |
| JP2001178817A (ja) | 1999-12-24 | 2001-07-03 | Terumo Corp | 人工腎臓用装置およびこれを用いた品質評価装置ならびに流体回路 |
| US7067060B2 (en) | 2000-01-11 | 2006-06-27 | Nephros, Inc. | Ionic enhanced dialysis/diafiltration system |
| JP2001190273A (ja) | 2000-01-14 | 2001-07-17 | Jsr Corp | ウイルス濃縮用粒子、該粒子を使用するウイルス濃縮方法およびウイルス検出方法 |
| GB0001450D0 (en) | 2000-01-21 | 2000-03-08 | Genpoint As | Cell isolation method |
| CA2400993C (en) | 2000-03-06 | 2011-06-07 | Dade Behring Marburg Gmbh | Carriers coated with polysaccharides, their preparation and use |
| EP1192963A4 (en) | 2000-04-05 | 2004-08-25 | Toray Industries | ADSORBENTS FOR PROTEINS OF THE HIGH MOBILITY PROTEIN AND PILLAR GROUP FOR CLEANING BODY LIQUIDS |
| US7181261B2 (en) | 2000-05-15 | 2007-02-20 | Silver James H | Implantable, retrievable, thrombus minimizing sensors |
| DE10045434B4 (de) | 2000-09-14 | 2005-07-14 | Fresenius Hemocare Gmbh | Adsorbens mit unterschiedlich modifizierten Oberflächenbereichen, Verfahren zu dessen Herstellung und Verwendung davon |
| JP4283430B2 (ja) * | 2000-09-26 | 2009-06-24 | 株式会社カネカ | エンテロトキシンの吸着材、吸着除去方法および吸着器 |
| US8178304B2 (en) * | 2000-10-06 | 2012-05-15 | Smith Terry J | Diagnostic methods relating to Graves' disease and other autoimmune disorders |
| US8153121B2 (en) * | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
| US6509104B2 (en) | 2000-12-05 | 2003-01-21 | Michigan Biotechnology Institute | Antithrombogenic polymer coating |
| EP1884274A1 (en) * | 2000-12-29 | 2008-02-06 | Upfront Chromatography A/S | Extracorporeal capturing of specific bio-macromolecular entities from extracellular body fluids |
| JP4138488B2 (ja) * | 2001-01-30 | 2008-08-27 | 株式会社カネカ | 直接血液灌流が可能な体液処理器 |
| DE10117043A1 (de) * | 2001-04-05 | 2002-11-07 | Gerhard Puetz | Verfahren zur Eliminierung von potentiell toxischen und/oder schädlichen Stoffen |
| US20020197252A1 (en) | 2001-04-10 | 2002-12-26 | Renal Tech International | Selective adsorption devices and systems |
| US6773412B2 (en) | 2001-04-13 | 2004-08-10 | Chf Solutions, Inc. | User interface for blood treatment device |
| JP2003128502A (ja) | 2001-10-18 | 2003-05-08 | Noritake Co Ltd | 有害物質の処理材およびその製造方法 |
| WO2003033143A1 (en) | 2001-10-10 | 2003-04-24 | Noritake Co.,Limited | Photocatalytic material selectively inactivating biologically harmful substance and utilization thereof |
| US8980568B2 (en) | 2001-10-11 | 2015-03-17 | Aviva Biosciences Corporation | Methods and compositions for detecting non-hematopoietic cells from a blood sample |
| US20030148017A1 (en) * | 2001-12-07 | 2003-08-07 | Olli Tuominen | Copolymer coating for a hydrophobic membrane |
| WO2003078023A1 (en) | 2002-03-14 | 2003-09-25 | Baxter International Inc. | Compound removal device |
| WO2003090781A1 (en) * | 2002-04-23 | 2003-11-06 | Meir Strahilevitz | Methods and devices for targeting a site in a mammal and for removing species from a mammal |
| JP2005532130A (ja) * | 2002-07-11 | 2005-10-27 | アップフロント・クロマトグラフィ・アクティーゼルスカブ | 敗血症治療のための体外流動膨張床方法 |
| US7348184B2 (en) | 2002-07-24 | 2008-03-25 | Bio-Rad Laboratories, Inc. | Protein interaction difference mapping |
| US7207964B2 (en) | 2003-03-17 | 2007-04-24 | Hemavation, Llc | Apparatus and method for down-regulating immune system mediators in blood |
| US20040182783A1 (en) | 2003-03-17 | 2004-09-23 | Walker Kimberly A. | Filter and concentrator device for treatment of blood |
| DK1654387T3 (da) | 2003-08-15 | 2009-06-22 | Univ South Florida | Materialer og fremgangsmåder til indfangning af patogener og fjernelse af aurintricarboxylsyre fra en pröve |
| US7399400B2 (en) | 2003-09-30 | 2008-07-15 | Nano-Proprietary, Inc. | Nanobiosensor and carbon nanotube thin film transistors |
| WO2005051313A2 (en) * | 2003-11-19 | 2005-06-09 | Chiron Corporation | Methods and reagents for treating, preventing and diagnosing bunyavirus infection |
| WO2006093524A2 (en) * | 2004-07-16 | 2006-09-08 | The General Hospital Corporation | Antigen-carbohydrate conjugates |
| US8272518B2 (en) * | 2004-07-23 | 2012-09-25 | Kaneka Corporation | Direct hemoperfusion adsorber packed with adsorbent having water insoluble microparticle removed therefrom, and method of obtaining direct hemoperfusion adsorbent having water insoluble microparticle removed therefrom |
| JP2008508952A (ja) * | 2004-08-04 | 2008-03-27 | アスピラ バイオシステムズ， インコーポレイテッド | 部分的分子インプリントを用いる体液からの生体分子の捕獲および除去 |
| EP1792635B1 (en) * | 2004-08-30 | 2014-05-21 | Kaneka Corporation | Granulocyte adsorbent |
| US8445293B2 (en) | 2005-02-09 | 2013-05-21 | Rapid Pathogen Screening, Inc. | Method to increase specificity and/or accuracy of lateral flow immunoassays |
| KR100972702B1 (ko) * | 2005-03-31 | 2010-07-27 | 도레이 카부시키가이샤 | 흡착재 및 체외 순환용 칼럼 |
| GB0509433D0 (en) * | 2005-05-09 | 2005-06-15 | Uni For Milj Og Biovitenskap | Method |
| EP2508867A1 (en) | 2005-06-24 | 2012-10-10 | Board Of Regents, The University Of Texas System | Systems and methods including self-contained cartridges with detection systems and fluid delivery systems |
| WO2008045021A2 (en) * | 2005-08-01 | 2008-04-17 | Rensselaer Polytechnic Institute | Blood compatible nanomaterials and methods of making and using the same |
| AU2006316039B2 (en) | 2005-11-21 | 2011-08-18 | Ge Healthcare Bio-Sciences Ab | A method of chromatography using semi-synthetic heparin ligands |
| AU2006325531B2 (en) | 2005-12-13 | 2012-04-19 | Exthera Medical Corporation | Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood |
| MX2008008281A (es) | 2005-12-21 | 2008-11-06 | Meso Scale Technologies Llc | Aparatos, metodos y reactivos de ensayo. |
| US8211048B2 (en) | 2006-02-22 | 2012-07-03 | Henry Ford Health System | System and method for delivery of regional citrate anticoagulation to extracorporeal blood circuits |
| WO2007146162A2 (en) | 2006-06-08 | 2007-12-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Devices, systems and methods for reducing the concentration of a chemical entity in fluids |
| WO2007145328A1 (ja) | 2006-06-16 | 2007-12-21 | Terumo Kabushiki Kaisha | 血液処理フィルターおよび血液処理回路 |
| FR2902670B1 (fr) * | 2006-06-22 | 2009-04-24 | Gambro Lundia Ab | Utilisation d'une suspension pour traiter un support a usage medical, support a usage medical, echangeur et dispositif d'adsorption comprenant le support |
| WO2008147382A1 (en) | 2006-09-27 | 2008-12-04 | Micronics, Inc. | Integrated microfluidic assay devices and methods |
| CA2667012A1 (en) | 2006-10-26 | 2008-05-02 | Abbott Laboratories | Immunoassay of analytes in samples containing endogenous anti-analyte antibodies |
| GB0702183D0 (en) | 2007-02-05 | 2007-03-14 | Iti Scotland Ltd | Pathogen binding |
| WO2008128251A1 (en) * | 2007-04-17 | 2008-10-23 | The Children's Hospital Of Philadelphia | Humanized viral vectors and methods of use thereof |
| AU2008242142A1 (en) | 2007-04-19 | 2008-10-30 | C.G.M.3 Ltd | Device system and method for monitoring and controlling blood analyte levels |
| WO2008155683A1 (en) | 2007-06-18 | 2008-12-24 | Firmenich Sa | Malodor counteracting compositions and method for their use |
| EP2167165B1 (en) | 2007-06-18 | 2014-09-24 | ExThera Medical Corporation | Full length heparin for restoration of the condition of blood |
| JP4226050B1 (ja) * | 2007-09-12 | 2009-02-18 | 株式会社Ｒｅｉメディカル | 体液浄化処理用吸着カラム |
| CN101952727A (zh) | 2007-12-31 | 2011-01-19 | 3M创新有限公司 | 微生物捕获用组合物和方法 |
| US11051733B2 (en) * | 2008-01-18 | 2021-07-06 | Wake Forest University Health Sciences | Isolating and purifying cells for therapy |
| EP2087916A1 (en) | 2008-02-11 | 2009-08-12 | ICinnovation BV | Electrosorption device for the purification of blood and other fluids |
| AU2009263046B2 (en) * | 2008-06-23 | 2014-07-24 | Temasek Polytechnic | A flow system of a dialysis device and a portable dialysis device |
| US20100021622A1 (en) | 2008-07-24 | 2010-01-28 | National Chiao Tung University | Apparatus and method for forming multilayer polymer thin film |
| US20100040546A1 (en) | 2008-08-13 | 2010-02-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Biological targeting compositions and methods of using the same |
| EA023912B1 (ru) | 2008-09-10 | 2016-07-29 | АйТиЭйч ИММЬЮН ТЕРАПИ ХОЛДИНГЗ АБ | Лечение воспалительных состояний |
| US8310415B2 (en) | 2008-09-30 | 2012-11-13 | Animas Corporation | Medical devices using bistable displays |
| US8430831B2 (en) * | 2009-02-25 | 2013-04-30 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
| US8801922B2 (en) | 2009-06-24 | 2014-08-12 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Dialysis system |
| DE112010003137T5 (de) | 2009-07-31 | 2012-06-06 | Board Of Regents, The University Of Texas System | Prophylaxe gegen krebsmetastasierung |
| CA2782311C (en) | 2009-12-01 | 2017-06-27 | Robert S. Ward | Method for removing cytokines from blood with surface immobilized polysaccharides |
| US20120305482A1 (en) | 2010-02-09 | 2012-12-06 | Exthera Medical, Llc | Removal of virulence factors through extracorporeal therapy |
| WO2011133287A1 (en) | 2010-04-19 | 2011-10-27 | The Trustees Of Columbia University In The City Of New York | Portable blood filtration devices, systems, and methods |
| EP2627369B1 (en) | 2010-10-15 | 2022-01-12 | SeaStar Medical, Inc. | Cytopheresic cartridge and use thereof |
| WO2012112724A1 (en) | 2011-02-15 | 2012-08-23 | Exthera Medical, Llc | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines |
| US20130131423A1 (en) | 2011-04-12 | 2013-05-23 | Tianxin Wang | Methods to detect and treat diseases |
| CN103857421B (zh) | 2011-06-13 | 2017-09-22 | Tla指标免疫疗法公司 | 治疗癌症的方法和在其中使用的结合试剂 |
| EP3081937B1 (en) | 2011-07-18 | 2019-11-13 | President and Fellows of Harvard College | Engineered microbe-targeting molecules and uses thereof |
| EP2556849A1 (en) | 2011-08-08 | 2013-02-13 | Gambro Lundia AB | Separation material |
| EP2861273B1 (en) | 2012-06-13 | 2017-08-23 | ExThera Medical Corporation | Use of heparin and carbohydrates to treat cancer |
| WO2014085713A1 (en) | 2012-11-30 | 2014-06-05 | The Methodist Hospital Research Institute | Methods and compositions for detecting tuberculosis |
| EP3013445B1 (en) | 2013-06-24 | 2019-11-06 | ExThera Medical Corporation | Blood filtration system containing mannose coated substrate |
| JP2016531874A (ja) | 2013-09-26 | 2016-10-13 | ファーマケア，インク． | オートタキシン阻害剤化合物 |
| MX382486B (es) | 2013-11-08 | 2025-03-13 | Exthera Medical Corp | Métodos para diagnosticar enfermedades infecciosas usando medio de adsorción. |
| JP2017513636A (ja) | 2014-04-24 | 2017-06-01 | エクスセラ メディカル コーポレイション | 高流量を用いて血液から細菌を除去するための方法 |
| US10857283B2 (en) | 2014-09-22 | 2020-12-08 | Exthera Medical Corporation | Wearable hemoperfusion device |
| JP7167168B2 (ja) | 2018-01-10 | 2022-11-08 | エックスダブリューファルマ リミテッド | ケタミンのプロドラッグ、組成物及びそれらの使用 |
| US20200023001A1 (en) | 2018-07-20 | 2020-01-23 | Northeastern University | GlycoFix (Structurally And Functionally Repaired Endothelial Glycocalyx) |
-
2010
- 2010-12-01 CA CA2782311A patent/CA2782311C/en active Active
- 2010-12-01 CN CN201610528098.7A patent/CN106178161B/zh active Active
- 2010-12-01 ES ES10787652T patent/ES2861359T3/es active Active
- 2010-12-01 KR KR1020127017243A patent/KR101716241B1/ko active Active
- 2010-12-01 EP EP10787652.6A patent/EP2509604B1/en active Active
- 2010-12-01 CN CN201080062777.0A patent/CN102740859B/zh active Active
- 2010-12-01 JP JP2012542164A patent/JP5925693B2/ja active Active
- 2010-12-01 CA CA2967094A patent/CA2967094C/en active Active
- 2010-12-01 US US12/958,355 patent/US8758286B2/en active Active
- 2010-12-01 KR KR1020147035273A patent/KR101876794B1/ko active Active
- 2010-12-01 WO PCT/US2010/058596 patent/WO2011068897A1/en not_active Ceased
- 2010-12-01 AU AU2010326028A patent/AU2010326028B2/en active Active
-
2014
- 2014-04-24 US US14/261,390 patent/US9408962B2/en active Active
-
2015
- 2015-10-13 JP JP2015201863A patent/JP6072189B2/ja active Active
-
2016
- 2016-06-30 US US15/199,737 patent/US10086126B2/en active Active
-
2018
- 2018-08-27 US US16/113,904 patent/US11123466B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102740859B (zh) | 2016-08-10 |
| US8758286B2 (en) | 2014-06-24 |
| CN106178161A (zh) | 2016-12-07 |
| US11123466B2 (en) | 2021-09-21 |
| JP5925693B2 (ja) | 2016-05-25 |
| KR101716241B1 (ko) | 2017-03-14 |
| WO2011068897A1 (en) | 2011-06-09 |
| JP2016034966A (ja) | 2016-03-17 |
| CA2967094A1 (en) | 2011-06-09 |
| CA2782311A1 (en) | 2011-06-09 |
| KR20150013310A (ko) | 2015-02-04 |
| AU2010326028A1 (en) | 2012-06-21 |
| KR101876794B1 (ko) | 2018-07-10 |
| WO2011068897A9 (en) | 2011-08-04 |
| US10086126B2 (en) | 2018-10-02 |
| US20140231357A1 (en) | 2014-08-21 |
| EP2509604B1 (en) | 2021-03-17 |
| JP2013512078A (ja) | 2013-04-11 |
| AU2010326028B2 (en) | 2014-10-02 |
| JP6072189B2 (ja) | 2017-02-01 |
| CN106178161B (zh) | 2020-12-22 |
| CN102740859A (zh) | 2012-10-17 |
| CA2782311C (en) | 2017-06-27 |
| US20160331886A1 (en) | 2016-11-17 |
| ES2861359T3 (es) | 2021-10-06 |
| KR20120103671A (ko) | 2012-09-19 |
| US9408962B2 (en) | 2016-08-09 |
| HK1177151A1 (zh) | 2013-08-16 |
| US20180361050A1 (en) | 2018-12-20 |
| EP2509604A1 (en) | 2012-10-17 |
| US20110184377A1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11123466B2 (en) | Methods for removing cytokines from blood with surface immobilized polysaccharides | |
| US10537280B2 (en) | Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines | |
| CN102791307B (zh) | 通过体外疗法除去毒力因子 | |
| AU2014277852B2 (en) | Method for removing cytokines from blood with surface immobilized polysaccharides | |
| HK1230116B (zh) | 使用固定於表面的多糖从血液中去除细胞因子的方法 | |
| HK1230116A1 (en) | Method for removing cytokines from blood with surface immobilized polysaccharides | |
| HK1177151B (en) | Method for removing cytokines from blood with surface immobilized polysaccharides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170510 |
|
| EEER | Examination request |
Effective date: 20170510 |
|
| EEER | Examination request |
Effective date: 20170510 |
|
| EEER | Examination request |
Effective date: 20170510 |